Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review)
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
About ACTEMRA® (tocilizumab) Treatment Info for Healthcare Professionals
Actemra | Uses, Safety Info & Comparison to Other RA Drugs
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia | SpringerLink
Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis | Therapeutic Delivery
Tocilizumab Raises GI Risks in Rheumatoid Arthritis | MedPage Today
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
A review of sarilumab for the treatment of rheumatoid arthritis | Immunotherapy
JCI - IL-6 polymorphisms: a useful genetic tool for inflammation research?
Figure 5 | The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond | Journal of Ophthalmic Inflammation and Infection | Full Text
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases - Tanaka - 2011 - FEBS Letters - Wiley Online Library
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases | SpringerLink
Immunomodulation as a potent COVID-19 pharmacotherapy | JIR
Clinical experience of IL-6 blockade in rheumatic diseases—Implications on IL-6 biology and disease pathogenesis - ScienceDirect
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Why tocilizumab could be an effective treatment for severe COVID-19? | Journal of Translational Medicine | Full Text
Frontiers | Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19 | Pharmacology
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? | Medicine
